NEXTHINK
28.10.2015 08:31:45 CET | Business Wire | Press release
Nexthink®, a pioneer and leader in end-user centric IT Operations Analytics (ITOA), today announced a partnership with Ymor , a leading APM service provider in the Netherlands. Under the agreement, Ymor will be able to provide consulting services, support and implement Nexthink’s IT analytics solutions for its customers.
Ymor unburdens customers through its Ketenbewaking™ service portfolio that protects and optimizes the IT environment by focusing on end-users. By integrating Nexthink’s technology into its offering, Ymor is able to expand and enhance its existing services. In addition to technical, configuration, end-to-end and component monitoring, Ymor can now offer its customers workspace monitoring. Nexthink’s visibility and IT analytics allow Ymor to provide control over the workspace that can lead to fast ROI and financial savings.
"As we strive for ‘end-user happiness,’ workplace monitoring is more important than ever before,” said Martin van den Berge, Director Ymor . “Throughout the workday, most end-users spend at least 5 hours using various applications. Performance issues cause frustration and lead to decreased efficiency for both end-users and the business. Working with Nexthink provides us with an opportunity to measure the end-user experience, to obtain a ‘helicopter view’ of the IT infrastructure, to quickly and easily find the root cause of issues and to achieve the goal of happy end-users.”
Ymor and Nexthink have implemented workplace monitoring with the city of The Hague. Gerard van Lieshout, Sr. Corporate IT Advisor of The Hague : “We use Nexthink to monitor all enterprise desktops, some 7,000 workspaces. By measuring delays, crashes and bottlenecks directly on the desktops, it gives us a better understanding on how our employees use the desktops. This not only allows us to respond better to reported incidents, but also to adjust configurations of the desktops before problems occur.”
“We are excited about the partnership with Ymor and extending our reach in Northern Europe,” said Nathan Wyld, Europe Channel Director at Nexthink . “As a result of this partnership, organisations in the Netherlands can benefit from Nexthink’s IT analytics and Ymor’s outstanding services and support for implementation and optimal use of IT analytics in their environments.”
###
About Ymor:
Ymor is a fast growing and innovative service provider based in Utrecht, which assists the Dutch Top 500 companies in improving the performance of complex IT environments with the goal of unburdening end-users. An organisation may be experiencing problems with performance or availability. It may be building a new application or wish to bring it online. Or there may simply be a need for the complex IT chain to be closely monitored. In all such cases the Ymor ‘Ketenbewaking’ service monitors and optimises the IT environment. Our slogan says it all: “Ymor creates user happiness!”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005061/en/
./ContentItem/FormatNexthink and Ymor partnership to meet demand for IT Analytics solutions in the Netherlands and significant customer win: city of The Hague
Contact:
Media contacts:
Nexthink
Victoria Calmon, +33 6
34 77 15 97
victoria.calmon@nexthink.com
www.nexthink.com
or
Ymor
Inge
Vollebregt, +31 610762591
ivollebregt@ymor.nl
www.ymor.nl
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom